Clinical trial
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
NCT04541082 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
- Lead sponsor
- Jazz Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- October 26, 2020
- Completion date
- December 31, 2026
- Enrollment
- 102 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anaplastic astrocytoma, anaplastic meningioma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, atypical meningioma, central nervous system neoplasms, choroid plexus neoplasms, diffuse astrocytoma, diffuse midline glioma, h3 k27m-mutant, ependymoma, ependymoma, anaplastic, glial tumor, glioblastoma, gliomatosis cerebri, gliosarcoma, adult, medulloblastoma, neuroectodermal tumors, neuroectodermal tumors, primitive, oligodendroglioma, pilocytic astrocytoma, pineal tumor, pleomorphic xanthoastrocytoma, teratoid rhabdoid tumor